

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

Atty.  
Dkt. No.

M#

Client Ref.

027579

0302598

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Gold, et al.

Appln. No.: 09/927,121

Filing Date: August 10, 2001

Date: March 16, 2004

Page

1

of

1

Examiner: Jessica H. Roark Group Art Unit: 1644

## U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
JR	A. 6,063,905	05/16/2000	Capra et al.			
	B.					
	C.					
	D.					
	E.					
	F.					
	G.					
	H.					

## FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
I.						
J.						
K.						
L.						
M.						
N.						

## OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

O.						
P.						
Q.						
R.						
S.						
T.						
U.						
V.						
W.						
X.						
Y.						
Z.						

Examiner

*JH*

Date Considered: 3/25/07

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

M#

Client Ref.

027579

0302598

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Applicant: Gold, et al.

Appln. No.: 09/927,121

Filing Date: August 10, 2001

Date: March 11, 2004

Page

1

of

9

Examiner: Jessica H. Roark Group Art Unit: 1644

**U.S. PATENT DOCUMENTS**

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
JWR	A.	4,338,397	07/06/1982	Gilbert et al.			
	B.	4,399,216	08/16/1983	Axel et al.			
	C.	4,444,878	04/24/1984	Paulus			
	D.	4,468,464	08/28/1984	Cohen et al.			
	E.	4,512,922	04/23/1985	Jones et al.			
	F.	4,634,665	01/06/1987	Axel et al.			
	G.	4,704,362	11/03/1987	Itakura et al.			
	H.	4,840,896	06/20/1989	Reddy et al.			
	I.	5,078,996	01/07/1992	Conlon III, et al.			
	J.	5,162,111	11/10/1992	Grabstein et al.			
	K.	5,179,017	01/12/1993	Axel et al.			
	L.	5,229,496	07/20/1993	Deeley et al.			
	M.	5,254,534	10/19/1993	Tachibana et al.			
	N.	5,334,379	08/02/1994	Pillai et al.			
	O.	5,478,556	12/26/1995	Elliott et al.			
	P.	5,580,561	12/3/1996	Cercek et al.			
	Q.	5,602,007	02/11/1997	Dunn et al.			
	R.	5,679,347	10/21/1997	Porcelli et al.			
	S.	5,728,377	03/17/1998	Sarris et al.			
	T.	5,891,429	04/06/1999	Clark et al.			
	U.	5,891,432	04/06/1999	Hoo			
	V.	5,895,646	04/20/1999	Wang			
	W.	5,900,238	05/04/1999	Gombotz et al.			
	X.	5,904,920	05/18/1999	Dranoff et al.			
	Y.	5,929,196	07/27/1999	Kissel et al.			
	Z.	5,942,221	08/24/1999	Clark et al.			
	AA.	5,942,253	08/24/1999	Gombotz et al.			
	BB.	5,980,911	11/09/1999	Corner et al.			
	CC.	6,080,409	06/27/2000	Laus et al.			
JWR	DD.	6,083,521	07/04/2000	Acemoglu et al.			

Examiner

Date Considered: 3/25/04

AMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

M#

Client Ref.

027579

0302598

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Applicant: Gold, et al.

Appln. No.: 09/927,121

Filing Date: August 10, 2001

Date: March 11, 2004

Page

2

of

9

Examiner: Jessica H. Roark Group Art Unit: 1644

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
JR	EE. 6,083,703	07/04/2000	Wang et al.			
	FF. 6,087,110	07/11/2000	Wang et al.			
	GG. 6,096,313	08/01/2000	Jäger et al.			
	HH. 6,120,807	09/19/2000	Gombotz et al.			
	II. 6,274,175 B1	08/14/2001	Gombotz et al.			
	JJ. 6,309,632 B1	10/30/2001	Agosti			
	KK. 6,312,718 B1	11/06/2001	Popescu et al.			
	LL. 6,331,415 B1	12/18/2001	Cabilly et al.			
	MM. 6,338,953 B1	01/15/2002	Boyce et al.			
	NN. 6,338,962	01/15/2002	Boyce			
	OO. 6,342,216 B1	01/29/2002	Fidler et al.			
	PP. 6,348,449 B1	02/19/2002	Weiner et al.			
JR	QQ. 6,361,948 B1	03/26/2002	Tricoli et al.			

**FOREIGN PATENT DOCUMENTS**

Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
JR RR. 2,139,756	01/20/1994	CA	Bonnem et al.		
SS. 0183350 B1	01/15/1992	EP	Anderson et al.		
TT. 0326149 B1	08/18/1993	EP	Tachibana et al.		
UU. 0370656 A1	05/30/1990	EP	Bonnem		
VV. 0382381 B1	05/26/1993	EP	Bonnem		
WW. 2658432 A1	08/23/1991	FR	Henri		
XX. 1-193227	08/03/1989	JP	Tachibana et al.	(Abstract Only) X	
YY. 6289621 62087621	04/24/1987	JP	Conlon et al.	(Abstract Only) X	
ZZ. 62230729	09/10/1987	JP	Takaharu et al.	(Abstract Only) X	
AAA. 02-002390	01/08/1990	JP	Matsuki et al.	(Abstract Only) X	
BBB. 64-027492	01/30/1989	JP	Boone	(Abstract Only) X	
CCC. 02-076820	03/16/1990	JP	Kishimoto et al.	(Abstract Only) X	
JR DDD. 2000-256209	09/19/2000	JP	Shimamura et al.	(Abstract Only) X	

Examiner

Date Considered: 3/29/04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office				Atty. Dkt. No.  <div style="text-align: center;">027579</div>	M#  <div style="text-align: center;">0302598</div>	Client Ref.  	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Applicant: Gold, et al.			
				Appln. No.: 09/927,121			
				Filing Date: August 10, 2001			
				Examiner: Jessica H. Roark    Group Art Unit: 1644			
Date: March 11, 2004      Page <span style="border: 1px solid black; padding: 0 5px;">3</span> of <span style="border: 1px solid black; padding: 0 5px;">9</span>							
FOREIGN PATENT DOCUMENTS						English Abstract	Translation Readily Available
		Document Number	Date MM/YYYY	Country	Inventor Name		
JWZ	EEE	88/00832	02/11/1988	WO	Grabstein		X
	FFF	91/05046	04/18/1991	WO	Smith		
	GGG	93/20835	10/28/1993	WO	Bonnem et al.		
	HHH	94/01133	01/20/1994	WO	Bonnem et al.	(Abstract Only)	X
	III	96/10395	04/11/1996	WO	Cox	(Abstract Only)	X
	JJJ	97/13502	04/17/1997	WO	Gombotz et al.		
JWZ	KKK	98/16246	04/23/1998	WO	Brem et al.		
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)							
JWZ	LLL	ACCOLLA, et al., "Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines," <u>Proc. Natl. Acad. Sci. USA</u> , 77(1):563-566 (1980)					
	MMM	ADAMS, et al., "Molecular Cloning of Mouse Immunoglobulin Heavy Chain Messenger Ribonucleic Acids Coding for $\mu$ , $\alpha$ , $\gamma 1$ , $\gamma 2a$ , and $\gamma 3$ Chains," <u>Biochemistry</u> , 19:2711-2719 (1980)					
	NNN	ADVANI, et al., "Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as an Adjunct to Autologous Hemopoietic Stem Cell Transplantation for Lymphoma," <u>Annals of Internal Medicine</u> , 116(3):183-189 (1992).					
	OOO	AMSTER, "Synthesis of part of a mouse immunoglobulin light chain in a bacterial clone," <u>Nucleic Acids Research</u> , 8(9):2055-2065 (1980)					
	PPP	AZUMA, et al., "Stimulation of Host-Defense Mechanism with Synthetic Adjuvants and Recombinant Cytokines Against Viral Infection in Mice," in Friedman, et al., ed., <u>Microbial Infections</u> , Plenum Press, New York, pp. 253-263 (1992).					
	QQQ	BACKMAN and PTASHNE, "Maximizing Gene Expression on a Plasmid Using Recombination in Vitro," <u>Cell</u> , 13:65-71 (1978)					
	RRR	BALTIMORE, et al., "Expression of the Abelson Murine Leukemia Virus Genome and of Transfected $\kappa$ Immunoglobulin Genes," <u>Journal of Cellular Biochemistry</u> , 12 <sup>th</sup> Annual UCLA Symposia Abstracts, Suppl. 7A, Abstract 0224 (1983)					
	SSS	BANERJI, et al., "Expression of a $\beta$ -Globin Gene Is Enhanced by Remote SV40 DNA Sequences," <u>Cell</u> , 27:299-308 (1981)					
	TTT	BENDANDI, "Role of anti-idiotypic vaccines in the modern treatment of human follicular lymphoma," <u>Expert Rev. Anticancer Ther.</u> , 1(1):65-72 (2001)					
	UUU	BERNARD, et al., "Sequences of Mouse Immunoglobulin Light Chain Genes before and after Somatic Changes," <u>Cell</u> 15:1133-1144 (1978)					
	VVV	BIXLER and PILLAI, "Augmentation by Interleukins of the Antibody Response to a Conjugate Vaccine Against <u>Haemophilus Influenza B</u> ," in Atassi, ed., <u>Immunobiology of Proteins and Peptides VI</u> , Plenum Press, New York, pp. 185-190 (1991)					
JWZ	WW	BONNEM, "Alpha Interferon: The Potential Drug of Adjuvant Therapy: Past Achievements and Future Challenges," <u>Eur. J. Cancer</u> , 27(Suppl. 4):S2-S7 (1991)					
Examiner <i>J. Roark</i>						Date Considered: 3/25/04	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office		Atty. Dkt. No.  <div style="text-align: center;">027579</div>	M#  <div style="text-align: center;">0302598</div>	Client Ref.  	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Applicant: Gold, et al.			
		Appln. No.: 09/927,121			
		Filing Date: August 10, 2001			
		Examiner: Jessica H. Roark    Group Art Unit: 1644			
Date: March 11, 2004      Page <div style="border: 1px solid black; padding: 0 5px;">4</div> of <div style="border: 1px solid black; padding: 0 5px;">9</div>					
FOREIGN PATENT DOCUMENTS				English Abstract	Translation Readily Available
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)					
22	XXX	BONNEM, "Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Biology and Potential Clinical Utility," in Oldham, ed., <u>Principles of Cancer Biotherapy</u> , 2 <sup>nd</sup> ed., Marcel Dekker, Inc., New York, Chapter 20, pp. 585-598 (1991)			
	YYY	BONNEM, "Granulocyte-macrophage colony stimulating factor - issues in patient management," in Maroun, et al., eds., <u>Colony-Stimulating Factors in Clinical Practice</u> , International Congress and Symposium Series Number 184, Royal Society of Medicine Services Limited, London, pp. 17-22 (1992)			
	ZZZ	BONNEM, "Granulocyte-Macrophage Colony-Stimulating Factor: Unrealized Potential," in Murphy, ed., <u>Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology</u> , AlphaMed Press, Dayton, Ohio, pp. 3-20 (1991)			
	AAA	BONNEM and MORSTYN, "Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Current Status and Future Development," <u>Seminars in Oncology</u> , 15(5)(Suppl. 5):46-51 (1988)			
	BBB	BONNEM, et al., "Summary of Preclinical/Clinical Phase I Studies with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)," <u>Investigational New Drugs: The Journal of New Anticancer Agents</u> , Abstract 235, 7(4):407 (1989)			
	CCC	BOSS and EMTAGE, "Expression of an Immunoglobulin Light Chain Gene in Escherichia Coli," <u>Gene Expression</u> , Alan R. Liss, Inc., New York, pp. 513-522 (1983)			
	DDD	CLARK and CROCE, "An Autonomously Replicating Vector for Mammalian Cells," <u>Plasmids and Transforming Vectors</u> , Fed Proc. 1983, Abstract 2364			
	EEE	COLMAN, et al., "Interactions of Mouse Immunoglobulin Chains within <u>Xenopus</u> Oocytes," <u>J. Mol. Biol.</u> , 160:459-474 (1982)			
	FFFF	DOLBY, et al., "Cloning and partial nucleotide sequence of human immunoglobulin $\mu$ chain cDNA from B cells and mouse-human hybridomas," <u>Proc. Natl. Acad. of Sci. USA</u> , 77(10):6027-6031 (1980)			
	GGG	DUMANN, et al., "Influence of Thymopentin on Antibody Response, and Monocyte and T Cell Function in Hemodialysis Patients Who Fail to Respond to Hepatitis B Vaccination," <u>Nephron</u> , 55:136-140 (1990)			
	HHH	FALKNER and ZACHAU, "Expression of mouse immunoglobulin genes in monkey cells," <u>Nature</u> , 298:286-288 (1982)			
	IIII	FRIEDMANN, et al., "Introduction Of The Human HPRT Gene Into Mammalian Cells By An Infectious Retroviral Vector," <u>Control of Phospholipid Metabolism</u> , Fed Proc. 1983, Abstract 1736			
	JJJJ	FUJISAWA, et al., "Direct expression of hepatitis B surface antigen gene in E. coli," <u>Nucleic Acids Research</u> , 11(11):3581-3591 (1983)			
(Abstract only) 22	KKK	FULIANO, et al., "La timopentina come terapia adiuvante nella vaccinazione anti-epatite B in soggetti non-O iporesponsivi," <u>Minerva Medica</u> , 81(5): 407-413 (1990)			
Examiner:		Date Considered: 3/25/01			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office		Atty. Dkt. No.  <div style="border: 1px solid black; padding: 2px; text-align: center;">027579</div>	M#  <div style="border: 1px solid black; padding: 2px; text-align: center;">0302598</div>	Client Ref.  <div style="border: 1px solid black; height: 40px;"></div>	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Applicant: Gold, et al.			
		Appln. No.: 09/927,121			
		Filing Date: August 10, 2001			
		Examiner: Jessica H. Roark    Group Art Unit: 1644			
Date: March 11, 2004      Page <div style="border: 1px solid black; padding: 0 5px;">5</div> of <div style="border: 1px solid black; padding: 0 5px;">9</div>					
FOREIGN PATENT DOCUMENTS				English Abstract	Translation Readily Available
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)					
JAL	LLLL	GILLIES, et al., "A Tissue-specific Transcription Enhancer Element is Located in the Major Intron of a Rearranged Immunoglobulin Heavy Chain Gene," <u>Cell</u> , 33:717-728 (1983)			
	MMM	GILLIES and TONEGAWA, "Expression of cloned immunoglobulin genes introduced into mouse L cells," <u>Nucleic Acids Research</u> , 11(22):7981-7997 (1983)			
	NNN	GLENNIE and STEVENSON, "Univalent antibodies kill tumour cells <u>in vitro</u> and <u>in vivo</u> ," <u>Nature</u> , 295:712-714 (1982)			
	OOO	GOUGH, "The rearrangements of immunoglobulin genes," in Tooze, et al., eds., <u>Trends in Biochemical Sciences</u> , Reference Edition, Vol. 6, International Union of Biochemistry and Elsevier/North-Holland, 1981, pp. 203-205			
	PPP	GOUGH, et al., "Molecular Cloning of Seven Mouse Immunoglobulin $\kappa$ Chain Messenger Ribonucleic Acids," <u>Biochemistry</u> , 19:2702-2710 (1980)			
	QQQ	GUARENTE, et al., "Improved Methods for Maximizing Expression of a Cloned Gene: a Bacterium That Synthesizes Rabbit $\beta$ -Globin," <u>Cell</u> , 20:543-553 (1980)			
	RRR	HEATH and PLAYFAIR, "Cytokines as immunological adjuvants," <u>Vaccine</u> , 10(7):427-434 (1992)			
	SSS	HESS, et al., "The effect of granulocyte-macrophage-colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients," <u>Journal of Viral Hepatitis</u> , 3:149-153 (1996)			
	TTT	HITZMAN, et al., "Secretion of Human Interferons by Yeast," <u>Science</u> , 219:620-625 (1983)			
	UUU	HOZUMI, et al., "Characterization of a mouse DNA clone containing an immunoglobulin variable region gene," <u>Nucleic Acids Research</u> , 5(6):1779-1799 (1978)			
	VVV	JAFEE, et al., "Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor - Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation," <u>Journal of Clinical Oncology</u> , 19(1):145-156 (2001)			
	WWW	KEMP and COWMAN, "Direct immunoassay for detecting <u>Escherichia coli</u> colonies that contain polypeptides encoded by cloned DNA segments," <u>Proc. Natl. Acad. Sci. USA</u> , 78(7):4520-4524 (1981)			
	XXX	KNUTH, et al., "Cellular and humoral immune responses against cancer: implications for cancer vaccines," <u>Current Opinion in Immunology</u> , 3:659-664 (1991)			
	YYY	KUROKAWA, et al., "Expression of human immunoglobulin E $\epsilon$ chain cDNA in <u>E. coli</u> ," <u>Nucleic Acids Research</u> , 11(10):3077-3085 (1983)			
	ZZZ	LAU and KAN, "Construction of Recombinant DNA Libraries Using Expression Cosmid Vectors That Can Shuttle Between Bacteria and Mammalian Cells," <u>Plasmids and Transforming Vectors</u> , Fed Proc. 1983, Abstract 2362, p. 2161			
JAL	AAA	LESLIE, et al., "Humoral immune responses in mice using gamma inulin preparations as adjuvants for hepatitis B vaccines," <u>Immunol. Cell Biol.</u> , 68:107-112 (1990)			
Examiner		Date Considered: 3/25/04			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

Atty.  
Dkt. No.

M#

Client Ref.

027579

0302598

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Applicant: Gold, et al.

Appln. No.: 09/927,121

Filing Date: August 10, 2001

Date: March 11, 2004

Page

6

of

9

Examiner: Jessica H. Roark Group Art Unit: 1644

**FOREIGN PATENT DOCUMENTS**

English  
Abstract

Translation  
Readily  
Available

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

JA2	BBB	LEVY, "Cytokine Fusion Proteins with Enhanced Immunogenicity," NIH Grant No. 1R01AI037219-01 (1994)				
	CCC	LIESCHKE and BURGESS, "Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor," Part 1, <u>New England Journal of Medicine</u> , 327(1): 28-35 (1992)				
	DDD	LIESCHKE and BURGESS, "Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor," Part 2, <u>New England Journal of Medicine</u> , 327(2): 99-106 (1992)				
	EEE	LIESCHKE, et al., "Effects of Bacterially Synthesized Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Advanced Malignancy," <u>Annals of Internal Medicine</u> , 110:357-364 (1989)				
	FFF	Summary in <u>Molecular Cloning, A Laboratory Manual</u> , Mantitis, et al., eds., Cold Spring Harbor Laboratory, New York (1982), p 433.				
	GGG	MARTIN, et al., "Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) in the Treatment of Chronic Hepatitis B," <u>American Association for the Study of Liver Diseases Abstracts of Papers</u> , 16(2, Pt. 2):67A, Abstract 89 (1992)				
	HHH	MASUCCI, et al., "CM-CSF Augments the Cytotoxic Activity of Mononuclear Cells in ADCC Using MAb 17-1A. Both $\alpha$ -IFN and TNF- $\alpha$ Acts Synergistically," Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 7-10, 1989, Abstract 143				
	IIII	MASUCCI, et al., "Chemotherapy and Immunotherapy of Colorectal Cancer," <u>Med. Oncol. &amp; Tumor Pharmacother.</u> , 8(3)207-220 (1991)				
	JJJJ	MASUCCI, et al., "Granulocyte-monocyte colony-stimulating factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A)," <u>Cancer Immunol. Immunother.</u> , 31:231-235 (1990)				
	KKK	McCUNE and MARQUIS, "Interleukin 1 as an Adjuvant for Active Specific Immunotherapy in a Murine Tumor Model," <u>Cancer Research</u> 50:1212-1215 (1990)				
	LLLL	MERCEREAU-PUIJALON, et al., "Expressions of Cloned Eukaryotic Genes in Microorganisms," in Pettersson et al., eds., <u>Expression of Eukaryotic Viral and Cellular Genes</u> , Academic Press, 1981, pp. 295-303				
	MMM	MEUER, et al., "Low-Dose Interleukin-2 Induces Systemic Immune Responses Against HBsAg in Immunodeficient Non-Responders to Hepatitis B Vaccination," <u>The Lancet</u> , January 7, 1989, pp. 15-18				
5112	NNN	MEUER, et al., "Monocyte Defect in Hemodialysis Patients Supports Nonresponsiveness to Hepatitis B Vaccination and Development of HBsAg Carrier State," in Zukerman, ed., <u>Viral Hepatitis and Liver Disease</u> , Alan R. Liss, Inc., New York, pp. 711-713 (1988)				

Examiner

Date Considered: 3/29/04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office		Atty. Dkt. No.  027579	M#  0302598	Client Ref.
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Applicant: Gold, et al.		
		Appln. No.: 09/927,121		
		Filing Date: August 10, 2001		
		Examiner: Jessica H. Roark    Group Art Unit: 1644		
Date: March 11, 2004      Page <span style="border: 1px solid black; padding: 0 5px;">7</span> of <span style="border: 1px solid black; padding: 0 5px;">9</span>				
FOREIGN PATENT DOCUMENTS				English Abstract
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)				Translation Readily Available
JW2	OOO	MEUER, et al., "Selective Blockade of the Antigen-Receptor-Mediated Pathway of T Cell Activation in Patients with Impaired Primary Immune Responses," <u>J. Clin. Invest.</u> 80:743-749 (1987)		
	PPP	MONK, et al., "Heavy-Chain Mutants Derived from Y <sub>2b</sub> Mouse Myeloma: Characterization of Heavy-Chain Messenger Ribonucleic Acid, Proteins, and Secretion in Deletion Mutants and Messenger Ribonucleic Acid in Y <sub>2a</sub> Mutant Progeny," <u>Biochemistry</u> , 20:2330-2339 (1981)		
	QQQ	MORRISON, "Transfer and Expression of Immunoglobulin Genes," <u>Ann. Rev. Immunol.</u> , 2:239-256, (1984)		
	RRR	MORRISSEY, et al., "Granulocyte-Macrophage Colony-Stimulating Factor Augments the Primary Antibody Response by Enhancing the Function of Antigen-Presenting Cells," <u>Journal of Immunology</u> , 139(4):1113-1119 (1987)		
	SSS	MORSTYN, et al., "Pharmacology of colony-stimulating factors," in Abbott, et al., eds., <u>Trends in Pharmacological Sciences</u> , 10:154-159 (1989)		
	TTT	MOXON, "The scope of immunisation," <u>The Lancet</u> , Feb. 24, 1990, pp. 448-451		
	UUU	MULLIGAN and BERG, "Expression of Bacterial Gene in Mammalian Cells," <u>Science</u> , 209:1422-1427 (1980)		
	VVV	MULLIGAN and BERG, "Selection for animal cells that express the <u>Escherichia coli</u> gene coding for xanthine-guanine phosphoribosyltransferase," <u>Proc. Natl. Acad. Sci. USA</u> , 78(4):2072-2076 (1981)		
	WWW	MYERS and GUSTAFSON, "Adjuvants for Human Vaccine Usage: A Rational Design," Chapter 32 in Cryz, ed., <u>Vaccines and Immunotherapy</u> , Pergamon Press, Inc., New York, 1991, pp. 404-410		
	XXX	NEUBERGER, "Expression and regulation of immunoglobulin heavy chain gene transfecting into lymphoid cells," <u>EMBO Journal</u> , 2(8):1373-1378 (1983)		
	YYY	NISONOFF and RIVERS, "Recombination of a Mixture of Univalent Antibody Fragments of Different Specificity," <u>Archives of Biochemistry and Biophysics</u> , Vol. 93, Academic Press, New York and London, pp. 460-462 (1961)		
	ZZZ	O'BRIEN et al., "Cloning and sequencing of the cDNA for ovine granulocyte-macrophage colony-stimulating factor (GM-CSF)," <u>Immunology and Cell Biology</u> 69:51-55 (1991)		
	AAA	OCHI et al., "Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells," <u>Proc. Natl. Acad. Sci. USA</u> , 80:6351-6355 (1983)		
	BBB	OCHI et al., "Transfer of a cloned immunoglobulin light-chain gene to mutant hybridoma cells restores specific antibody production," <u>Nature</u> 302:340-342 (1983)		
JW2	CCC	OI et al., "Immunoglobulin gene expression in transformed lymphoid cells," <u>Proc. Natl. Acad. Sci. USA</u> , 80:825-829 (1983)		
Examiner <i>J. Roark</i>		Date Considered: 3/25/04		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.				



FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

Atty.  
Dkt. No.

M#

Client Ref.

027579

0302598

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Applicant: Gold, et al.

Appln. No.: 09/927,121

Filing Date: August 10, 2001

Date: March 11, 2004

Page

8

of

9

Examiner: Jessica H. Roark Group Art Unit: 1644

**FOREIGN PATENT DOCUMENTS**

English  
Abstract

Translation  
Readily  
Available

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

JH2	DDD	OKAYAMA and BERG, "A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells," <i>Molecular and Cellular Biology</i> 3(2):280-289 (1983)			
	EEE	PARDOLL, "Gene-Targeted Immunotherapy of Renal Cancer," Grant No. 1U01CA061551-01 (Abstract), <a href="http://commons.cit.nih.gov/crisp3/CRISP_LIB">http://commons.cit.nih.gov/crisp3/CRISP LIB</a> , accessed 9/4/2002			
	FFF	PELLICER et al., "Altering Genotype and Phenotype by DNA-Medicated Gene Transfer," <i>Science</i> , 209:1414-1421 (1980)			
	GGG	PICARD and SCHAFFNER, "Correct transcription of a cloned mouse immunoglobulin gene in vivo," <i>Proc. Natl. Acad. Sci. USA</i> , 80:417-421 (1983)			
	HHH	QUIROGA et al., "Recombinant $\gamma$ -Interferon as Adjuvant to Hepatitis B Vaccine in Hemodialysis Patients," <i>Hepatology</i> , 12(4):661-663 (1990)			
	IIIII	RASO and GRIFFIN, "Hybrid Antibodies with Dual Specificity for the Delivery of Ricin to Immunoglobulin-bearing Target Cells," <i>Cancer Research</i> , 41:2073-2078 (1981)			
	JJJJ	REEVES et al., "Construction and Transfer Into Mammalian Cells of a Vector Containing Insect Histone Genes," in Lurquin, et al., eds., <i>Genetic Engineering in Eukaryotes</i> , Plenum Press, New York, pp. 73-85 (1983)			
	KKK	RICE et al., "Expression of Immunoglobulin Genes Introduced into Mouse Lymphoid Cell Lines," <i>Journal of Cellular Biochemistry, Suppl. 7A</i> :133 (Abstract 0341) (1983)			
	LLLL	RICE and BALTIMORE, "Regulated expression of an immunoglobulin $\kappa$ gene introduced into a mouse lymphoid cell line," <i>Proc. Natl. Acad. Sci. USA</i> , 79:7862-7865 (1982)			
	MMM	ROBERTS, "A <i>lac</i> Promoter System for the Overexpression of Prokaryotic and Eukaryotic Genes in <i>E. Coli</i> ," in Rodriguez, et al., eds., <i>Promoters, Structure and Function</i> , Praeger Publishers, New York, 1982, pp. 452-461			
	NNN	ROBERTS, et al., "Synthesis of simian virus 40 t antigen in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 76(11):5596-5600 (1979)			
	OOO	ROBERTS, et al., "A general method for maximizing the expression of a cloned gene," <i>Proc. Natl. Acad. Sci. USA</i> , 76(2):760-764 (1979)			
	PPP	SAMBROOK, et al., "Cloning into Bacteriophage M13 Vectors and Transfection of Competent Bacteria," in <i>Molecular Cloning, A Laboratory Manual</i> , 2 <sup>nd</sup> ed., Cold Spring Harbor Laboratory Press, New York, 1989, pp. 4.33-4.34			
	QQQ	SCHRADER, "Peptide Regulatory Factors and Optimization of Vaccines," <i>Molecular Immunology</i> , 28(3):295-299 (1991)			
	RRR	SIMS, et al., "Somatic Mutation in Genes for the Variable Portion of the Immunoglobulin Heavy Chain," <i>Science</i> , 216:309-311 (1982)			
JH2	SSS	SOUTHERN and BERG, "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter," <i>Journal of Molecular and Applied Genetics</i> , 1:327-341 (1982)			

Date Considered: 3/25/04

Examiner

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

M#

Client Ref.

027579

0302598

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Applicant: Gold, et al.

Appln. No.: 09/927,121

Filing Date: August 10, 2001

Date: March 11, 2004

Page

9

of

9

Examiner: Jessica H. Roark Group Art Unit: 1644

**FOREIGN PATENT DOCUMENTS**

English  
Abstract

Translation  
Readily  
Available

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

TTT	STAFFORD and QUEEN, "Cell-type specific expression of a transfected immunoglobulin gene," <u>Nature</u> , 306:77-79 (1983)				
UUU	STEWART, et al., "Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions -- a phase I dose-toxicity study," <u>Br. J. Cancer</u> , 59:142-145 (1989)				
VVV	STEWART, et al., "Clinical Studies with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>International Journal of Cell Cloning</u> , 8:335-346, Suppl. 1 (1990)				
WW	SUBRAMANI, "Expression of the Mouse Dihydrofolate Reductase Complementary Deoxyribonucleic Acid in Simian Virus 40 Vectors," <u>Molecular and Cell Biology</u> , 2:854-864 (1981)				
XXX	SULLIVAN and MANDELL, "The role of cytokines in infection," <u>Current Opinion in Infectious Diseases</u> , 4:344-349 (1991)				
YYY	TANIGUCHI, et al., "Expression of the human fibroblast interferon gene in <u>Escherichia coli</u> ," <u>Proc. Natl. Acad. Sci. USA</u> , 77(9):5230-5233 (1980)				
ZZZ	TONEGAWA, "Somatic Generation of Immune Diversity," Nobel lecture, December 8, 1987				
AAA	VALLE, et al., "Synthesis and secretion of mouse immunoglobulin chains from <u>Xenopus</u> oocytes," <u>Nature</u> , 291:338-340 (1981)				
BBB	VALLE, et al., "Anti-ovalbumin monoclonal antibodies interact with their antigen in internal membranes of <u>Xenopus</u> oocytes," <u>Nature</u> , 300:71-74 (1982)				
CCC	VOSE, et al., "Granulocyte-monocyte colony-stimulating factor (GM-CSF): Answers or More Questions?," <u>Annals of Internal Medicine</u> , 116(3):261-262 (1992)				
DDD	WETZEL, et al., "Expression in <u>Escherichia coli</u> of a chemically synthesized gene for a "mini-C" analog of human proinsulin," <u>Gene</u> , 16:63-71 (1981)				
EEE	WIGLER, et al., "Transformation of Mammalian Cells with Genes from Prokaryote and Eucaryotes," <u>Cell</u> , 16:777-785 (1979)				
FFF	WILLIAMS, et al., "Cytoplasmic Inclusion Bodies in <u>Escherichia coli</u> Producing Biosynthetic Human Insulin Proteins," <u>Science</u> , 215:687-689 (1982)				
GGG					
HHH					
IIII					
JJJJ					

Examiner

Date Considered: 3/25/04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
027579	0302598	

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Applicant: Gold, et al.	
Appln. No.: 09/927,121	
Filing Date: August 10, 2001	
Examiner: Jessica H. Roark	Group Art Unit: 1644

Date: December 16, 2003 Page 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
JW2	AR 5,679,356	10/21/1997	Bonnem			
	BR					
	CR					
	DR					
	ER					
	FR					
	GR					
	HR					
	IR					

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
JW2	JR 0351876 A2	01/24/1990	EP	Kishimoto		
	KR					
	LR					

**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

JW2	MR	ALTMANN, et al., "Insect Cells as Hosts for the Expression of Recombinant Glycoproteins," <i>Glycoconjugate Journal</i> , 16:109-123 (1999)			
JW2	NR	SCHRADER, "Peptide Regulatory Factors and Optimization of Vaccines," <i>Molecular Immunology</i> , 28(3):295-299 (1991)			
JW2	OR	WALSH, "Biopharmaceutical Benchmarks - 2003," <i>Nature Biotechnology</i> , 21(8):865-870 (2003)			
	PR				
	QR				
	RR				
	SR				
	TR				
	UR				
	VR				
	WR				
	XR				

Examiner *J Roark* Date Considered: 3/1/04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

APR 03 2002

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

11

Application Number

09/927,121

Filing Date

August 10, 2001

First Named Inventor

Gold

Group Art Unit

TBA

Examiner Name

TBA

Attorney Docket Number

032077.0003.UTL1

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
JHR	AA	3,969,287		Boehringer Mannheim GmbH	7/13/1976	
	AB	4,195,128		Bayer Aktiengesellschaft	3/25/1980	
	AC	4,229,537		New York University	10/21/1980	
	AD	4,247,642		Sumitomo Chem. Co.	1/27/1981	
	AE	4,330,440		Development Finance Corp. of New Zealand	5/18/1982	
	AF	4,661,586		The Board of Trustees of the Leland Stanford Junior University	4/28/1987	
	AG	4,745,051		The Texas A&M University System	5/17/1988	
	AH	4,816,397		Celltech Limited	3/28/1989	
	AI	5,053,224		Koprowski et al.	10/1/1991	
	AJ	5,122,464		Celltech Limited; The University Court of the Univ. of Glasgow	6/16/1992	
	AK	5,227,159		Richard A. Miller	7/13/1993	
	AL	5,281,699		Tanox Biosystems, Inc.	1/25/1994	
	AM	5,612,035		The Immune Response Corporation	3/18/1997	
	AN	5,650,150		Stephen D. Gillies	7/22/1997	
	AO	5,789,206		Myriad Genetics, Inc.	8/4/1998	
	AP	5,792,445		Bracco International B.V.	8/11/1998	
	AQ	5,861,164		The Immune Response Corp.	1/19/1999	
JHR	AR	5,972,334		Genitope Corp.	10/26/1999	

Examiner  
Signature

JHR

Date

Considered

3/29/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

APR 09 2002

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0951-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 11

## **Complete if Known**

Application Number 09/927,121  
Filing Date August 10, 2001  
First Named Inventor Gold  
Group Art Unit TBA  
Examiner Name TBA  
Attorney Docket Number 032077.0003.UTL1

RECEIVED  
APR 10 2002  
CENTRAL RECORDS

## **U.S. PATENT DOCUMENTS**

JMR	AS	6,099,846	The Board of Trustees of the Leland Stanford Junior University	8/8/2000	
-----	----	-----------	--	----------	--

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
JMR	AT	EP	0874054	A2		3/4/98		
	AU	JP	10-295379			11/10/98		
JMR	AV	WO	00/06733	A2	Heska Corp.	2/10/2000		
JMR	AW	WO	00/47228		The Scripps Research Institute	8/17/2000		
JMR	AX	WO	92/08495		Abbott Biotech, Inc.	5/29/1992		
JMR	AY	WO	97/29769		Biomira USA Inc.	8/21/1997		
JMR	AZ	WO	97/35008		The Gov't. of the U.S.A., rep. by The Dept. of Health & Human Services	9/25/1997		
JMR	BA	WO	98/30577	A1	Board of Regents, The Univ. of Texas System	7/16/1998		
JMR	BB	WO	99/29732		Lexigen Pharm. Corp.	6/17/1999		
JMR	BC	WO	99/46392		The Gov't. of the U.S.A., rep. by The Dept. of Health & Human Services	9/16/1999		
JMR	BD	WO	99/52562		Lexigen Pharm. Corp.	10/21/1999		
JMR	BE	WO	99/57981		Sloan-Kettering Institute for Cancer Research	11/18/1999		

Examiner Signature	<i>[Signature]</i>	Date Considered	3/29/01
-----------------------	--------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0003.UTL1

Sheet 3 of 11

TECH CENTER 1500/1999

APR 0 3 2002

RECEIVED

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JNR	BF	ARDEN, et al., "Human T-Cell Receptor Variable Gene Segment Families," <u>Immunogenetics</u> , 42:455-500 (1995)	
JNR	BG	BENDANDI, et al., "Complete Molecular Remissions Induced by Patient-specific Vaccination Plus Granulocyte-monocyte Colony-stimulating Factor Against Lymphoma," <u>Nature Medicine</u> , 5:1171-1177 (1999)	
JNR	BH	BERINSTEIN, et al., "Idiotypic Variation in a Human B Lymphoma Cell Line," <u>The Journal of Immunology</u> , Vol. 144, No. 2: 752-758 (1990)	
JNR	BI	BROWN, et al., "Antiidiotype Antibody Therapy of B-Cell Lymphoma," <u>Seminars in Oncology</u> , 16:199-210 (1989)	
JNR	BJ	BROWN, et al., "The Prognostic Significance of Immunophenotype in High-grade Non-Hodgkin's Lymphoma," <u>Histopathology</u> , Vol. 14: 621-627 (1989)	
JNR	BK	BROWN, et al., "Treatment of B-Cell Lymphomas with Anti-idiotypic Antibodies Alone and in Combination with Alpha Interferon," <u>Blood</u> , 73(3):651:661 (1989)	
JNR	BL	CAMPBELL, et al., "Idiotypic Vaccination Against Murine B Cell Lymphoma, Humoral and Cellular Requirements for the Full Expression of Antitumor Immunity," <u>The Journal of Immunology</u> , 145:1029-1036 (1990)	
JNR	BM	CAMPBELL, et al., "Immunotherapy of Established Murine B Cell Lymphoma, Combination of Idiotypic Immunization and Cyclophosphamide," <u>The Journal of Immunology</u> , 141:3227-3233 (1988)	
JNR	BN	CARAYANNOPOULOS, et al., "Recombinant Human IgA Expressed in Insect Cells," <u>Proc. Natl. Acad. Sci.</u> , Vol. 91: 8348-8352 (1994)	
JNR	BO	CASARES, et al., "Antigen-specific Downregulation of T Cells by Doxorubicin Delivered through a Recombinant MHC II-peptide Chimera," <u>Nature Biotechnology</u> , 19:142-147 (2001)	
JNR	BP	CASPAR, et al., "Idiotypic Vaccines for Non-Hodgkin's Lymphoma Induce Polyclonal Immune Responses That Cover Mutated Tumor Idiotypes: Comparison of Different Vaccine Formations," <u>Blood</u> , Vol. 90, No. 9, pp. 3699-3706 (November 11, 1997)	

Examiner Signature

*[Signature]*

Date Considered


3/25/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 11

## Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0003.UTL1

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JMR	BQ	CATON, et al., "Influenza Virus Hemagglutinin-specific Antibodies Isolated from a Combinatorial Expression Library are closely related to the Immune Response of the Donor," <u>Proc. Natl. Acad. Sci.</u> , Vol. 88: 6450-6454 (1990)	
JMR	BR	CHEN and LEVY, "Induction of Autoantibody Responses to GM-CSF by Hyperimmunization with an Id-GM-CSF Fusion Protein," <u>The Journal of Immunology</u> , 154, pp. 3105-3117 (1995)	
JMR	BS	CHEN, et al., "Idiotypic-Cytokine Fusion Proteins as Cancer Vaccines, Relative Efficacy of IL-2, IL-4, and Granulocyte-Macrophage Colony-Stimulating Factor," <u>The Journal of Immunology</u> , 153:4775-4787 (1994)	
JMR	BT	CHESON, et al., "Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas," <u>J. Clin. Oncol.</u> , 17(4):1244 (1999)	
JMR	BU	CHUNDURU, "Exploitation of the Vβ8.2 T Cell Receptor in Protection against Experimental Autoimmune Encephalomyelitis Using a Live Vaccinia Virus Vector," <u>J. Immunol.</u> , 156:4940-45, (1996)	
JMR	BV	CHUNG, et al., "Functional three-domain single-chain T-cell receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 91:12654-12658 (1994)	
JMR	BW	CLARK, et al., "Comparison of Human and Mouse T-Cell Receptor Variable Gene Segment Subfamilies," <u>Immunogenetics</u> , 42:531-540 (1995)	
JMR	BX	CLEARY, et al., "Clustering of Extensive Somatic Mutations in the Variable Region of an Immunoglobulin Heavy Chain Gene from a Human B Cell Lymphoma," <u>Cell Press</u> , Vol. 44: 97-106 (1986)	
JMR	BY	DALEY, et al., "Idiotypic-Specific Transplantation Resistance to MOPC-315: Abrogation by Post-Immunization Thymectomy," <u>The Journal of Immunology</u> , vol. 120, No. 5 (1978)	
JMR	BZ	DOENECKE, et al., "Rapid Amplification of cDNA ends (RACE) Improves the PCR-based Isolation of Immunoglobulin Variable Region Genes from Murine and Human Lymphoma Cells and Cell Lines," <u>BTS Leukemia</u> , 11:1787-1792 (1997)	
JMR	CA	DRANOFF, et al., "Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity," <u>Proc. Natl. Acad. Sci. USA</u> , 90(8):3539-3543 (1993)	
JMR	CB	EILAT, et al., "Secretion of a soluble, chimeric γδ T-cell receptor – immunoglobulin heterodimer," <u>Proc. Natl. Acad. Sci. USA</u> , 89:6871-6875 (1992)	


Examiner Signature	Date Considered
<i>[Signature]</i>	3/29/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0003.UTL1

Sheet 5 of 11

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JMR	CC	ENGEL, et al., "High-Efficiency Expression and Solubilization of Functional T Cell Antigen Receptor Heterodimers," <u>Science</u> , 256:1318-1321 (1992)	
JMR	CD	GEORGE, et al., "Idiotypic Vaccination as a Treatment for a B Cell Lymphoma," <u>The Journal of Immunology</u> , Vol. 141: 2168-2174 (1988)	
JMR	CE	GILLIES, et al., "Biological Activity and in Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , 4:230-235 (1993)	
JMR	CF	GOLD, Daniel P., "TCR V Gene Usage in Autoimmunity," <u>Current Opinion in Immunology</u> , 6:907-912 (1994)	
JMR	CG	GOLD, et al., "T-Cell Receptor Peptides as Immunotherapy for Autoimmune Disease," <u>Critical Reviews Immunol.</u> , 17:507-10 (1997)	
JMR	CH	GRABSTEIN, et al., "Induction of Macrophage Tumoricidal Activity by Granulocyte-Macrophage Colony-Stimulating Factor," <u>Science</u> , Vol. 232:506-508 (1986)	
JMR	CI	GREENBERG, Philip D., "Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells," <u>Advances in Immunology</u> , 49:281-355 (1991)	
JMR	CJ	GREGOIRE, et al., "Engineered secreted T-cell receptor $\alpha\beta$ heterodimers," <u>Proc. Natl. Acad. Sci USA</u> , Vol. 88, pp. 8077-8081 (September 1991)	
JMR	CK	HASEMANN, et al., "High-level Production of a Functional Immunoglobulin Heterodimer in a Baculovirus Expression System," <u>Proc. Natl. Acad. Sci.</u> , 87:3942-3946 (1990)	
JMR	CL	HASEMANN, et al., "Mutational Analysis of Arsonate Binding by a CRI <sub>A</sub> Antibody, V <sub>H</sub> and V <sub>L</sub> Junctional Diversity are Essential for Binding Activity," <u>The Journal of Biological Chemistry</u> , 266:7626-7632 (1991)	
JMR	CM	HASEMANN, et al., "Mutational Analysis of the Cross-Reactive Idiotypic of the A Strain Mouse," <u>The Journal of Immunology</u> , 147:3170-3179 (1991)	
JMR	CN	HEUFLER, et al., "Granulocyte/Macrophage Colony-Stimulating Factor and Interleukin 1 Mediate the Maturation of Murine Epidermal Langerhans Cells into Potent Immunostimulatory Dendritic Cells," <u>J. Exp. Med.</u> , 167(2):700-05 (1988)	

Examiner Signature

*[Signature]*

Date

Considered

3/29/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

APR 03 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 11

Application Number 09/927,121  
Filing Date August 10, 2001  
First Named Inventor Gold  
Group Art Unit TBA  
Examiner Name TBA  
Attorney Docket Number 032077.0003.UTL1

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JNR	CO	HINUMA, et al., "A Novel Strategy for Converting Recombinant Viral Protein into High Immunogenic Antigen," <u>Federation of European Biochemical Societies</u> , 288:138-142 (1991)	
JNR	CP	HSU, et al., "Tumor-Specific Idiotypic Vaccines in the Treatment of Patients with B-Cell Lymphoma - Long-Term Results of a Clinical Trial," <u>Blood</u> , Vol. 89, No. 9, pp. 3129-35 (May 1, 1997)	
JNR	CQ	HSU, et al., "Vaccination of Patients with B-cell Lymphoma Using Autologous Antigen-pulsed Dendritic Cells," <u>Nature Medicine</u> , 2:52-58 (1996)	
JNR	CR	HUSE, et al., "General of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 246(4935):1275-1281 (1989)	
JNR	CS	JIANG, et al., "Murine CD8+ Cells that Specifically Delete Autologous CD4+ T Cells Expressing Vb8 TCR: A Role of the Qa-1 Molecule," <u>Immunity</u> , 2:185-94 (1995)	
JNR	CT	KAPPLER, et al., "Binding of a soluble $\alpha\beta$ T-cell receptor to superantigen/major histocompatibility complex ligands," <u>Proc. Natl. Acad. Sci. USA</u> , 91:8462-8466 (1994)	
JNR	CU	KUMAR, et al., "Recombinant T Cell Receptor Molecules Can Prevent and Reverse Experimental Autoimmune Encephalomyelitis," <u>J. Immunol.</u> , 159:5150-5156 (1997)	
JNR	CV	KURUCZ, et al., "A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 90:3830-3834 (1993)	
JNR	CW	KWAK, et al., "Combined Syngeneic Bone Marrow Transplantation and Immunotherapy of a Murine B-Cell Lymphoma: Active Immunization with Tumor-Derived Idiotypic Immunoglobulin," <u>Blood</u> , 76(11):2411-2417 (1990)	
JNR	CX	KWAK, et al., "Idiotypic Vaccination as Therapy for Multiple Myeloma," <u>Seminars in Hematology</u> , 36:34-37 (1999)	
JNR	CY	KWAK, et al., "Introduction of Immune Responses in Patients with B-Cell Lymphoma Against the Surface-Immunoglobulin Idiotypic Expressed by Their Tumors," <u>N. Eng. J. Med.</u> , 327:1209-1215 (1992)	
JNR	CZ	KWAK, et al., "Transfer of Myeloma Idiotypic-specific Immunity from an Actively Immunised Marrow Donor," <u>The Lancet</u> , 345:1016-1020 (1995)	

Examiner Signature

*[Signature]*

Date

Considered

3/24/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	09/927,121
			Filing Date	August 10, 2001
			First Named Inventor	Gold
			Group Art Unit	TBA
			Examiner Name	TBA
			Attorney Docket Number	032077.0003.UTL1
Sheet	7	of	11	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JWR	DA	KWAK, et al., "Vaccination with Syngeneic, Lymphoma-derived Immunoglobulin Idiotypic Combined with Granulocyte/Macrophage colony-stimulating Factor Primes Mice for a Protective T-cell Response," <u>Proc. Natl. Acad. Sci.</u> , 93:10972-10977 (1996)	
JWR	DB	LEBOWITZ, et al., "Soluble, High-Affinity Dimers of T-Cell Receptors and Class II Major Histocompatibility Complexes: Biochemical Probes for Analysis and Modulation of Immune Responses," <u>Cell. Immun.</u> , 192:175-184 (1999)	
JWR	DC	LEVITISKY, et al., "Immunization with Granulocyte-Macrophage Colony-Stimulating Factor-Transduced, but Not B7-1-Transduced, Lymphoma Cells Primes Idiotypic-Specific T Cells and Generates Potent Systemic Antitumor Immunity," <u>J. Immunol.</u> , 156 (10):3858-3865 (1996)	
JWR	DD	LEVY, et al., "Mutational Hot Spots in Ig V Region Genes of Human Follicular Lymphomas," <u>J. Exp. Med.</u> , 168(2):475-489 (1988)	
JWR	DE	LIN, et al., "Expression of T Cell Antigen Receptor Heterodimers in a Lipid-Linked Form," <u>Science</u> , 249:677-679 (1990)	
JWR	DF	MAECKER and LEVY, "Spontaneous T Cell Antigen Receptor Variants of a Human T Leukemia Cell Line," <u>J. Immunol.</u> , 141:2994-3002, (1985)	
JWR	DG	MALKOVSKA, et al., "Human T Cells in hu-PBL-SCID Mice Proliferate in Response to Daudi Lymphoma and Confer anti-tumour Immunity," <u>Clin. Exp. Immunol.</u> , 96:158-165 (1994)	
JWR	DH	MALONEY, et al., "Monoclonal Anti-Idiotypic Antibody Therapy of B-Cell Lymphoma: The Addition of a Short Course of Chemotherapy Does Not Interfere With the Antitumor Effect Nor Prevent the Emergence of Idiotypic-Negative Variant Cells," <u>Blood</u> , 80(6):1502-1510 (1992)	
JWR	DI	MASSAIA, et al., "Idiotypic Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy," <u>Blood</u> , 94:673-683 (1999)	
JWR	DJ	MCKEEVER, et al., "Immunization with Soluble BDC 2.5 T Cell Receptor-Immunoglobulin Chimeric Protein: Antibody Specificity and Protection of Nonobese Diabetic Mice against Adoptive Transfer of Diabetes by Maternal Immunization," <u>J. Exp. Med.</u> , 184:1755-1768 (1996)	
JWR	DK	MEEKER, et al., "A Clinical Trial of Anti-Idiotypic Therapy for B Cell Malignancy," <u>Blood</u> , 65:1349-1363 (1985)	
Examiner Signature	Date Considered		3/29/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/927,121
		Filing Date	August 10, 2001
		First Named Inventor	Gold
		Group Art Unit	TBA
		Examiner Name	TBA
		Attorney Docket Number	032077.0003.UTL1
Sheet	8	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JNR	DL	MEEKER, et al., "Emergence of Idiotype Variants During Treatment of B-Cell Lymphoma with Anti-Idiotype Antibodies," <u>N. Eng. J. Med.</u> , 312:1658-1665 (1985)	
JNR	DM	MILLER, et al., "Treatment of B-Cell Lymphoma with Monoclonal Anti-idiotype Antibody," <u>N. Eng. J. Med.</u> , 306(9):517-522 (1982)	
JNR	DN	MINTY, et al., "Molecular Cloning of the MCP-3 Chemokine Gene and Regulation of its Expression," <u>Eur. Cytokine Netw.</u> , 4(2):99-110 (1993)	
JNR	DO	MORRISSEY, et al., "Granulocyte-Macrophage Colony-Stimulating Factor Augments the Primary Antibody Response by Enhancing the Function of Antigen-Presenting Cells," <u>J. Immunol.</u> , 139(4):1113-1119 (1987)	
JNR	DP	MROCZKOWSKI, et al., "Secretion of Thermostable DNA Polymerase Using a Novel Baculovirus Vector," <u>J. Biol. Chem.</u> , 269:13522-13528 (1994)	
JNR	DQ	MULLINAX, et al., "Identification of Human Antibody Fragment Clones Specific for Tetanus Toxoid in a Bacteriophage A Immunoexpression Library," <u>Proc. Natl. Acad. Sci. USA</u> , 87(20):8095-8099 (1990)	
JNR	DR	NELSON, et al., "Tumor-Specific, Cytotoxic T-Lymphocyte Response After Idiotype Vaccination for B-Cell, Non-Hodgkin's Lymphoma," <u>Blood</u> , 88:580-589 (1996)	
JNR	DS	NESBIT, et al., "Production of a Functional Monoclonal Antibody Recognizing Human Colorectal Carcinoma Cells from a Baculovirus Expression System," <u>Immunol. Methods</u> , 151:201-208 (1992)	
JNR	DT	NOVOTNY, et al., "A soluble, single-chain T-cell receptor fragment endowed with antigen-combining properties," <u>Proc. Natl. Acad. Sci. USA</u> , 88:8646-8650 (1991)	
JNR	DU	O'HERRIN, et al., "Analysis of the Expression of Peptide - Major Histocompatibility Complexes Using High Affinity Soluble Divalent T Cell Receptors," <u>J. Exp. Med.</u> , 186(8):1333-1345 (1997)	
JNR	DV	ODENDAHL, et al., "Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus," <u>J. Immunol.</u> , 165(10):5970-5979 (2000)	
JNR	DW	OFFNER, et al., "Vaccination with BV8S2 Protein Amplifies TCR-Specific Regulation and Protection Against Experimental Autoimmune Encephalomyelitis in TCR BV8S2 Transgenic Mice," <u>J. Immunol.</u> , 161:2178-2186 (1998)	


Examiner Signature		Date Considered	3/29/07
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/927,121
		Filing Date	August 10, 2001
		First Named Inventor	Gold
		Group Art Unit	TBA
		Examiner Name	TBA
Sheet 9 of 11	Attorney Docket Number	032077.0003.UTL1	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JAR	DX	OGAWA, et al., "Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ Cells in Peripheral Blood Derived from Patients with Autoimmune Hepatitis or Chronic Hepatitis C with Autoimmune Phenomena," <u>J. Gastroenterol. Hepatol.</u> , (1):69-75 (2000)	
JAR	DY	OKADA, et al., "TCR Vaccines for Active Immunotherapy of T Cell Malignancies," <u>J. Immunol.</u> , 159:5516-5527 (1997)	
JAR	DZ	OPDENAKKER, et al., "Human Monocyte Chemotactic Protein-3 (MCP-3): Molecular Cloning of the cDNA and Comparison with other Chemokines," <u>Biochem. Biophys. Res. Comm.</u> , 191(2):535-542 (1993)	
JAR	EA	ORLANDI, et al., "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction," <u>Proc. Natl. Acad. Sci. USA</u> , 86(10) 3833-3837 (1989)	
JAR	EB	POTTER, et al., "Anti-idiotypic Antibody D12 and Superantigen SPA Both Interact with Human V <sub>H</sub> 3-encoded Antibodies on the External Face of the Heavy Chain Involving FR1, CDR2, and FR3," <u>Molecular Immunology</u> , 35:1179-1187 (1998)	
JAR	EC	POTTER, et al., "Staphylococcal Protein A Binding to V <sub>H</sub> 3 Encoded Immunoglobulins," <u>Intern. Rev. Immunol.</u> , 14:291-308 (1997)	
JAR	ED	POTTER, et al., "Staphylococcal Protein A Simultaneously Interacts with Framework Region 1, Complementarity-Determining Region 2, and Framework Region 3 on Human V <sub>H</sub> 3- Encoding Igs <sup>1</sup> ," <u>The Journal of Immunology</u> , 157:2982-2988 (1996)	
JAR	EE	POTTER, et al., "The Cross-Reactive Idiotypes Recognized by the Monoclonal Antibodies 9G4 and LC1 are Located in Framework Region 1 of Two Non-Overlapping Subsets of Human V <sub>H</sub> 4 Family Encoded Antibodies," <u>Scand. J. Immunol.</u> , 40:43-49 (1994)	
JAR	EF	PROOST, et al., "Human Monocyte Chemotactic Proteins-2 and -3: Structural and Functional Comparison with MCP-1," <u>J. Leukoc. Biol.</u> , 59(1):67-74 (1996)	
JAR	EG	RAUER and KAISER, "Demonstration of Anti-HuD Specific Oligoclonal Bands in the Cerebrospinal Fluid from Patients with Paraneoplastic Neurological Syndromes Qualitative Evidence of Anti-HuD Specific IgG-synthesis in the Central Nervous System," <u>J. Neuroimmunol.</u> , 111(1-2):241-244 (2000)	
JAR	EH	ROWEN, et al., "The Complete 685-Kilobase DNA Sequence of the Human $\beta$ T Cell Receptor Locus," <u>Science</u> , 272:1755-1762 (1996)	
JAR	EI	RUBERTI, et al., "The Use of the RACE Method to Close Hybridoma cDNA when V Region Primers Fail," <u>Journal of Immunological Methods</u> , 173:33-39 (1994)	
JAR	EJ	SAKATO, et al., "Suppression of MOPC-167 Growth <i>In Vivo</i> by Immunization Against the Idiotypic of the MOPC-167 Myeloma Protein," <u>Microbiol. Immunol.</u> , 23:927-931 (1979)	

Examiner Signature	<i>[Signature]</i>	Date Considered	3/29/04
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	09/927,121
				Filing Date	August 10, 2001
				First Named Inventor	Gold
				Group Art Unit	TBA
				Examiner Name	TBA
Sheet	10	of	11	Attorney Docket Number	032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DNR	EK	SANTOLI, et al., "Amplification of IL-2-Driven T Cell Proliferation by Recombinant Human IL-3 and Granulocyte-Macrophage Colony-Stimulating Factor," <u>J. Immunol.</u> , 141(20):519-526 (1988)	
DNR	EL	SINCLAIR, et al., "PCR Strategies for Isolation of the 5' End of an Immunoglobulin-encoding Bovine cDNA," <u>Gene</u> , 167:285-289 (1995)	
DNR	EM	SINGH and O'HAGAN, "Advances in Vaccine Adjuvants," <u>Nature Biotech.</u> , 17:1075-1081 (1999)	
DNR	EN	SMITH, et al., "Direct Evidence for an Intracellular Role for IFN-γ" Microinjection of Human IFN-γ Induces Ia Expression on Murine Macrophages, <u>J. Immunol.</u> , 144(5):1777-1782 (1990)	
DNR	EO	STEVENSON and GORDON, "Immunization with Idiotype Immunoglobulin Protects Against Development of B Lymphocytic Leukemia, But Emerging Tumor Cells can Evade Antibody Attack by Modulation," <u>J. Immunol.</u> , 130(2):970-973 (1983)	
DNR	EP	TAO and LEVY, "Idiotypic/granulocyte-macrophage Colony-stimulating Factor Fusion Protein as a Vaccine for B-Cell Lymphoma," <u>Nature</u> , 362(6422):755-758 (1993)	
DNR	EQ	TESSIER, et al., "Enhanced Secretion from Insect Cells of a Foreign Protein Fused to the Honeybee Melittin Signal Peptide," <u>Gene</u> , 98:177-183 (1991)	
DNR	ER	VAN HALL, et al., "Identification of a Novel Tumor-Specific CTL Epitope Presented by RMA, EL-4, and MBL-2 Lymphomas Reveals Their Common Origin," <u>J. Immunol.</u> , 165:869-877 (2000)	
DNR	ES	VAINIENE, et al., "Natural Immunodominant and Experimental Autoimmune Encephalomyelitis-Protective Determinants Within the Lewis Rat Vβ8.2 Sequence Include CDR2 and Framework 3 Idiotypes," <u>Journal of Neuroscience Research</u> , 43:137-145 (1996)	
DNR	ET	VANDENBARK, et al., "Human TCR as Antigen: Homologies and Potentially Cross-Reactive HLA-DR2-Restricted Epitopes Within the AV and BV CDR2 Loops," <u>Critical Reviews Immunol.</u> , 20:57-83 (2000)	
DNR	EU	WAISMAN, et al., "Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity," <u>Nature Med.</u> , 2(8):899-905 (1996)	
DNR	EV	WARE, et al., "Human CD8+ Lymphocyte Clones Specific for T Cell Receptor VB Families Expressed on Autologous CD4+ T Cells," <u>Immunity</u> , 2:177-184 (1995)	
DNR	EW	WARREN and CATZ, "Kinetic Profiles of Cerebrospinal Fluid Anti-MBP in Response to Intravenous MBP Synthetic Peptide DENP <sub>85</sub> VVHFFKNIVTP <sub>96</sub> RT in Multiple Sclerosis Patients," <u>Mult. Scler.</u> , 6(5):300-311 (2000)	


Examiner Signature		Date Considered	3/25/07
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/927,121
				Filing Date	August 10, 2001
				First Named Inventor	Gold
				Group Art Unit	TBA
				Examiner Name	TBA
Sheet	11	of	11	Attorney Docket Number	032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JHR	EX	WEBER, et al., "Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor," <u>Nature</u> , 356:793-796 (1992)	
JHR	EY	WILSON, et al., "Results of a phase I clinical trial of T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations," <u>J. Neuroimmunol.</u> , 76:15-28 (1997)	
JHR	EZ	YOUNG, et al., "Comparison of the Effects of IL-3, Granulocyte-Macrophage Colony-Stimulating Factor, and Macrophage Colony-Stimulating Factor in Supporting Monocyte Differentiation in Culture," <u>J. Immunol.</u> , 145(2):607-615 (1990)	
JHR	FA	ZHANG, et al., "Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic L:upus Erythematosys," <u>J. Immunol.</u> , 166(1):6-10 (2001)	
JHR	FB	ZHANG, et al., "Increased Frequency of Interleukin 2-responsive T Cells Specific for Myelin Basic Protein and Proteolipid Protein in Peripheral Blood and Cerebrospinal Fluid of Patients with Multiple Sclerosis," <u>J. Exp. Med.</u> , 179:973-984 (1994)	

Examiner Signature		Date Considered	3/25/07
--------------------	--	-----------------	---------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.